All In Biotech

Drug Trial Radar · NCT07858123

Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma

A 52-Week, Randomised, Double-Blind, Double-Dummy, Multinational, Multicenter, Active-Controlled, 2-Arm Parallel Group Study Comparing CHF5993 100/6/12.5 μg pMDI (Fixed Combination of Extrafine Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide) to Seretide® Evohaler® 125/25 μg pMDI (Fixed Combination of Fluticasone Propionate/Salmeterol Xinafoate) in Adolescent Subjects With Uncontrolled Asthma on Medium Doses of Inhaled Corticosteroids in Combination With Long-Acting β2-Agonists

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Nov 16, 2026

Primary completion

Jun 26, 2030

Study completion Jun 26, 2030

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CLI-05993AA5-06 study is an interventional study designed to investigate the safety and efficacy of a new experimental drug called CHF5993 pMDI compared to the currently approved Seretide 125 Evohaler pMDI in adolescent patients with uncontrolled asthma.

Conditions

  • Asthma

Interventions

  • CHF5993 100/6/12.5 μg pMDI HFA-152aDrug

    Drug: CHF5993 100/6/12.5 μg pMDI HFA-152a administered via Pressurized Metered Dose Inhaler (pMDI). Active ingredients: Beclomethasone Dipropionate (BDP)//Formoterol Fumarate (FF) /Glycopyrronium Bromide (GB) 100/6/12,5μg per actuation; Excipients: HFA-152a propellant.

  • Seretide EvohalerDrug

    Drug: Seretide Evohaler administered via Pressurized Metered Dose Inhaler (pMDI). Active ingredients: Fluticasone Propionate (FP)/Salmeterol Xinafoate (SLM) pMDI 125/25μg per actuation; Excipients: HFA-134a propellant.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in pre-dose Forced Expiratory Volume FEV1 in the first second (FEV1).Time frame: Baseline (pre-dose on Week 0) and Week 26

Locations

25 sites in 3 countries. Site status is shown where the registry gives one.

  • Institute for Respiratory Diseases Medaimun GmbH

    Frankfurt, Germany

  • Georg-August-Universität Göttingen

    Göttingen, Germany

  • Universitätsklinikum Jena

    Jena, Germany

  • Centre for Congenital Heart Defects Stuttgart, Paediatric Intensive Care, Pulmonology and Allergology

    Stuttgart, Germany

  • ASST Spedali Civili Brescia

    Brescia, Italy

  • "A. Perrino" Hospital

    Brindisi, Italy

  • Istituto Giannina Gaslini Pediatric Allergic Center,

    Genoa, Italy

  • University of Messina G. Martino Hospital, Allergy and Clinical Immunology Unit

    Messina, Italy

  • Buzzi Children Hospital

    Milan, Italy

  • Federico II University, Department of Translational Medical Sciences, Section of Pediatrics

    Naples, Italy

  • IPAS (Respiratory Diseases of Pediatric Interest) University of Campania 'Luigi Vanvitelli',

    Naples, Italy

  • University Hospital of Parma

    Parma, Italy

  • University Hospital of Pisa, Pediatrics Unit

    Pisa, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Woman and Child Health and Public Health

    Roma, Italy

  • Bambino Gesù Pediatric Hospital IRCCS, Allergy Division

    Rome, Italy

  • IRCCS Humanitas Research Hospital

    Rozzano, Italy

  • Hospital Universitario Germans Trias

    Badalona, Spain

  • Hospital Sant Joan de Deu

    Barcelona, Spain

  • Vall d'Hebron University Hospital

    Barcelona, Spain

  • Hospital General Universitario Santa Lucia

    Cartagena, Spain

  • Hospital Universitario De Jerez Servicio de Pediatría

    Jerez de la Frontera, Spain

  • Hospital Universitario Infanta Leonor

    Madrid, Spain

  • Hospital Universitario Severo Ochoa

    Madrid, Spain

  • Hospital Clínico Universitario de Santiago de Compostela

    Santiago de Compostela, Spain

  • IMED Valencia

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.